Eli Lilly and (LLY)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from LLY's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Eli Lilly and's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Net income | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| Free cash flow | — | — | — | — | — |
| EPS (diluted) | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| Operating margin | — | — | — | — | — |
Where the revenue comes from
Revenue by products, fiscal 2025.
Superinvestors who own LLY
From each investor's latest 13F filing (what a 13F shows). 12 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| PRIMECAP Management PRIMECAP Management Co |
Trimmed | $11.0B | 6.5% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | $1.2B | 0.43% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Added | $580M | 0.48% | Q2 2026 |
| Ron Baron Baron Capital (BAMCO) |
Added | $169M | 0.25% | Q2 2026 |
| Larry Robbins Glenview Capital Management |
New position | $69M | 1.3% | Q2 2026 |
| Dodge & Cox Dodge & Cox |
Trimmed | $49M | 0.03% | Q2 2026 |
| Mario Gabelli GAMCO Investors |
Added | $33M | 0.30% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Added | $26M | 0.06% | Q2 2026 |
| Stanley Druckenmiller Duquesne Family Office |
New position | $15M | 0.28% | Q2 2026 |
| Eric Marshall Hodges Capital Management |
Added | $13M | 0.86% | Q2 2026 |
| Murray Stahl Horizon Kinetics LLC |
Trimmed | $5M | 0.05% | Q2 2026 |
| Bill Nygren Harris Associates LP |
Trimmed | $516,954 | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by Eli Lilly and's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Feb 26, 2026 | David Taylor |
0 | $1,022.16 | — |
| Feb 26, 2026 | David Taylor |
0 | $1,022.16 | — |
| Feb 26, 2026 | David Taylor |
0 | $1,022.16 | — |
| Jan 23, 2026 | Ro Khanna |
0 | $1,065.05 | — |
| Jan 23, 2026 | Ro Khanna |
0 | $1,065.05 | — |
| Jan 23, 2026 | Ro Khanna |
0 | $1,065.05 | — |
| Dec 29, 2025 | Markwayne Mullin |
0 | $1,078.72 | — |
| Dec 29, 2025 | Angus S. King Jr. |
0 | $1,078.72 | — |
| Dec 29, 2025 | Markwayne Mullin |
0 | $1,078.72 | — |
| Dec 29, 2025 | Angus S. King Jr. |
0 | $1,078.72 | — |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when LLY trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
Are Eli Lilly and insiders buying the stock?
10 open-market insider purchases of LLY in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Eli Lilly and?
12 of the superinvestors Investingly tracks hold LLY in their latest 13F, including PRIMECAP Management, Cliff Asness, Hersh Cohen.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.